Company Filing History:
1 out of 61 
1 out of 932 
Years Active: 2021
Title: Aron Roxin: Innovator in Prostate Cancer Research
Introduction
Aron Roxin is a notable inventor based in Norman, OK (US), recognized for his contributions to the field of cancer research. His innovative work primarily focuses on developing compounds that target the prostate-specific membrane antigen (PSMA), which is crucial in the treatment of prostate cancer.
Latest Patents
Roxin holds a patent for 18/19F-labelled compounds that specifically target PSMA. This patent discloses novel compounds comprising a zwitterionic trifluoroborate prosthetic group designed to target PSMA in prostate cancer. The compounds have a specific formula, wherein each R1 is an anionic group, L is a linker, and R2B-F3 is —N(R)CHBF, which includes a pyridinium group substituted with BFor methyl BF, or an azole group substituted with methyl BF3. The patent also outlines methods and uses for imaging and treating PSMA-expressing cancers.
Career Highlights
Throughout his career, Aron Roxin has worked with prestigious institutions, including the British Columbia Cancer Agency Branch and The University of British Columbia. His experience in these organizations has significantly contributed to his expertise in cancer research and innovation.
Collaborations
Roxin has collaborated with Kuo-shyan Lin, enhancing his research efforts and expanding the impact of his work in the field of cancer treatment.
Conclusion
Aron Roxin's innovative contributions to prostate cancer research through his patented compounds demonstrate his commitment to advancing medical science. His work continues to pave the way for new treatment options for patients suffering from prostate cancer.